Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells

Erythromycin and its fourteen-member macrolide analogues have attracted attention for their efficacy in bronchial asthma. However, their mechanisms of action remain unclear. We evaluated the effects of the macrolide antibiotics on endothelin-1 (ET-1) expression in normal and transformed human bronchial epithelial cells, one of the sources of this potent bronchoconstrictor important in the pathogenesis of asthma. Human bronchial epithelial cells were obtained from the resected bronchi, and the effect of several antimicrobial and antiasthmatic drugs on the production and messenger ribonucleic acid (mRNA) levels of ET-1 was evaluated. Bronchoepithelial cells were also isolated from the mucosa of asthmatic patients under fibreoptic bronchoscopy, and the modulating effects of the drugs were studied. Erythromycin and clarithromycin uniquely suppressed mRNA levels as well as the release of ET- at therapeutic and non-cytotoxic concentrations (percentage inhibition of ET-1 protein release: 26.4+/-5.22% and 31.2+/-7.45%, respectively, at 10(-6) M). Furthermore, erythromycin and clarithromycin inhibited ET-1 expression in bronchoepithelial cells from patients with chronic, stable asthma. A glucocorticosteroid, dexamethasone, also inhibited ET-1 expression. In contrast, theophylline, salbutamol and FK506 had no effect on ET-1 production. Our findings demonstrated that these fourteen-member macrolide antibiotics had an inhibitory effect on endothelin-1 expression in human bronchial epithelial cells. Moreover, this new mode of action may have some relevance to their clinical efficacy in bronchial asthma.

This article has been cited by other articles:

				B. Houweling, D. Merkus, O. Sorop, F. Boomsma, and D. J. Duncker Role of endothelin receptor activation in secondary pulmonary hypertension in awake swine after myocardial infarction J. Physiol., July 15, 2006; 574(2): 615 - 626. [Abstract] [Full Text] [PDF]

				S. Ragab, G. K. Scadding, V. J. Lund, and H. Saleh Treatment of chronic rhinosinusitis and its effects on asthma Eur. Respir. J., July 1, 2006; 28(1): 68 - 74. [Abstract] [Full Text] [PDF]

				E. Kostadima, S. Tsiodras, E.I. Alexopoulos, A.G. Kaditis, I. Mavrou, N. Georgatou, and A. Papamichalopoulos Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma Eur. Respir. J., May 1, 2004; 23(5): 714 - 717. [Abstract] [Full Text] [PDF]

				M. Desaki, H. Okazaki, T. Sunazuka, S. Omura, K. Yamamoto, and H. Takizawa Molecular Mechanisms of Anti-Inflammatory Action of Erythromycin in Human Bronchial Epithelial Cells: Possible Role in the Signaling Pathway That Regulates Nuclear Factor-{kappa}B Activation Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1581 - 1585. [Abstract] [Full Text] [PDF]

				J. S. ERJEFÄLT and C. G. A. PERSSON New Aspects of Degranulation and Fates of Airway Mucosal Eosinophils Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 2074 - 2085. [Full Text]

				H. Takizawa, M. Tanaka, K. Takami, T. Ohtoshi, K. Ito, M. Satoh, Y. Okada, F. Yamasawa, and A. Umeda Increased expression of inflammatory mediators in small-airway epithelium from tobacco smokers Am J Physiol Lung Cell Mol Physiol, May 1, 2000; 278(5): L906 - L913. [Abstract] [Full Text] [PDF]